Manganese X
Subsidiary JV Partner PureBiotic AIR Provides Positive Updated Data
on Virginia State University Testing On An Important Range Of
Pathogens And Biofilm, Including COVID -19
Montréal,
Québec, Canada, October 14th, 2021 -- InvestorsHub NewsWire
-- Manganese X Energy Corp. (TSXV: MN) (FSE: 9SC) (OTCQB: MNXXF)("Manganese X", "MN",
the "Company") is pleased to announce that its wholly owned
subsidiary, Disruptive Battery Corp. (DBC), in conjunction with its
US Joint Venture Partner, PureBiotic AIR, Corp (PureBiotic), has received additional positive
results from its ongoing long-term research study conducted by
Virginia State University (VSU). This has been despite the delays
caused by the COVID-19 restrictions which have been affecting most
university campuses and research facilities.
It should be noted that after
receiving additional positive results the Company will soon be
announcing a series of registrations, certifications and regulatory
product applications of significant interest.
Martin Kepman, CEO comments: "We
continue to evolve our misting solution for the mitigation of
pathogens including COVID-19. Research is showing positive
efficacy. We are now moving towards making additional
certifications including applying for FDA approval".
In the VSU's latest round of
testing, the priority was documenting the risk reduction on an
important range of pathogens and biofilm, including COVID
-19, utilizing the
PureBiotic Mist Solution on surfaces, in addition to air. The VSU
researchers have produced effective and encouraging results on the
PureBiotics Solution's effect on biofilm. This is important to note
since the Centers for Disease Control and Prevention (CDC)
has rated biofilm, where pathogens
like COVID-19 and other pathogens are found, to be responsible for
some 80% of all infections. Biofilm provides a protective
environment for pathogens from disinfectants and antibiotics. The
deconstruction of biofilm removes the "protective home" and
therefore helps protect against COVID 19 and other
contaminants.
Also of importance, the University
laboratory was able to recently produce growths of different types
of biofilms required for testing of the PureBiotic AIR HVAC
Delivery System for the mitigation of other types of infection
risks, such as COVID-19. This testing showed that the PureBiotic
Mist can be effective in helping to deconstruct biofilm in an HVAC
setting.
In addition to the recent tests
administered by VSU, the University research team compiled and
researched all other testing completed to date by a wide variety of
hospitals, universities, and other organizations. This research has
proven that the PureBiotics technology has the ability to simply,
easily & economically control Salmonella, Escherichia coli (E.
coli), Staphylococcus, MRSA 90%, Pseudomonas 82%, Candida Spp. 90%,
Coliforms 92%, Acinetobacter spp. 78%, etc. It was also observed that the effect of
suppression caused by the PureBiotic Formulation was stable over
the course of time. Demonstrating that the reduction of pathogens
in the environment resulted in a corresponding reduction in
nosocomial infections over a relatively long period of
time.
With
these new studies and former research re-confirming the
effectiveness of the PureBiotics Technologies, VSU is adding
testing sites to their on-going study. These tests will determine
how economically viable the PureBiotics Formulations are in
eliminating the risk of infections, with the additional benefits of
providing safer, cleaner and odor free
facilities.
Former VSU
Research on PureBiotics Solution's Effectiveness
PureBiotic Solutions came to the
attention of the VSU lab in 2018, when several production
facilities in Indiana and Georgia that were using PureBiotics
products, requested testing for controlling
Salmonella, a pathogen that accounts for a large number of
illnesses & hospitalizations in the USA annually. This was
followed up by VSU with further testing for Aspergillus, a common
mold that kill an estimated 1.5 million people globally each year
and sicken many millions more. Both these series of tests on the
use of the PureBiotic Solutions were successful.
In testing against a wide group of
chemical disinfectants currently used in hospitals, the PureBiotics
formulations proved to be from 78% to 92% more effective, depending
on the type of infection risk to eradicate.
The company is not making any
express or implied claim that it has developed a COVID-19 air
management solution at this time.
About
Manganese X Energy Corp.
Manganese X's mission
is to advance its Battery Hill project into production, with the
intent of supplying value-added materials to the lithium-ion
battery and other alternative energy industries, The Company is
also striving to achieve new carbon-friendly more efficient
methodologies, while processing manganese at a lower competitive
cost. The company
is the only publicly traded manganese company in North America
moving rapidly toward commercialization of a manganese deposit.
Subsidiary Disruptive
Battery Corp.'s mission is to develop an HVAC (heating, ventilation
and air conditioning) air purification delivery system for cleaner
and healthier air, aiming to mitigate COVID-19 and other
contaminants on surfaces and in the air. For more information visit the website at
www.manganesexenergycorp.com
On behalf of the Board of
Directors of
MANGANESE X
ENERGY CORP.
Martin Kepman
CEO and Director
Email:
martin@kepman.com
Tel: 1-514-802-1814
Cautionary
Note Regarding Forward-Looking Statements:
Neither TSX
Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this
release.
This news
release contains "forward-looking information" including statements
with respect to the future exploration performance of the Company.
This forward-looking information involves known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements of the Company to be materially
different from any future results, performance or achievements of
the Company, expressed or implied by such forward-looking
statements. These risks, as well as others, are disclosed within
the Company's filing on SEDAR, which investors are encouraged to
review prior to any transaction involving the securities of the
Company.
Forward-looking
information contained herein is provided as of the date of this
news release and the Company disclaims any obligation, other than
as required by law, to update any forward-looking information for
any reason. There can be no assurance that forward-looking
information will prove to be accurate, and the reader is cautioned
not to place undue reliance on such forward-looking information. We
seek safe harbor.
